AAPL News 96.45 07/15/2014 04:22:13 Apple Inc (AAPL)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Apple Inc (AAPL) 96.45 $AAPL

'Fast Money' Recap: Will Apple's Next Phone Be Delayed?
at The Street - 21 mins ago
The trading panel discussed the iPhone 6, bank stocks and Alibaba.

You Can't Ignore This iPhone 6 Feature
Ashraf Eassa, The Motley Fool - Motley Fool - Mon Jul 14, 10:47PM CDT
One of the most interesting parts of Apple 's upcoming iPhone 6 will be the A8 system on a chip found inside. Though there's been a lot of speculation as to what exactly this chip will look like, there was speculation recently that suggested that...

Smartphones Can Take This Tech Stock to New Highs
Harsh Chauhan, The Motley Fool - Motley Fool - Mon Jul 14, 9:00PM CDT
It is difficult to find much fault with Tigress Financial analyst Ivan Feinseth, who recently downgraded Synaptics from a "strong buy" to "buy" citing reduced upside potential. Synaptics shares have run up close to 70% in 2014, and since June 11,...

Could This Be the Best Growth Stock of the Next Decade?
Adam Galas, The Motley Fool - Motley Fool - Mon Jul 14, 8:00PM CDT
GT Advanced Technologies is one of Wall Street's hottest stocks since Apple   picked the company to manufacture sapphire for some of its upcoming products. Source:  GTAT data by YCharts In the last year, the company has almost...

Jim Cramer's 'Mad Money' Recap: An 'F' for Not Paying Attention
at The Street - Mon Jul 14, 7:28PM CDT
Every day the market is incorrectly valuing stocks, Cramer complains.

Apple, Intel Among 4 Techs Flexing Relative Strength
at Investor's Business Daily - Mon Jul 14, 7:25PM CDT
Tech firms stand out in IBD Bolting RS Lines Screen of the Day, which compares a stock's price performance against the S&P 500. Silicon Valley giant Apple (AAPL) is expected to release new products later this year, specifically larger 4.7-inch and...


Got a rash? iPad, other devices might be the cause
By LINDSEY TANNER - AP - Mon Jul 14, 7:24PM CDT
CHICAGO (AP) — Unexplained rash? Check your iPad. It turns out the popular tablet computer may contain nickel, one of the most common allergy-inducing metals.

Apple's Inc.'s Older iPhone 5s Is Beating Samsung's New Galaxy S5
Daniel Sparks, The Motley Fool - Motley Fool - Mon Jul 14, 7:03PM CDT
The first major sign Samsung may be significantly underperforming near-term expectations came when it offered pre-earnings guidance earlier this month to warn investors of a massive 24% decline in operating profits. The company cited currency...

3 Apple Suppliers Poised for Outperformance
Piyush Arora, The Motley Fool - Motley Fool - Mon Jul 14, 6:30PM CDT
Apple 's iPhone 6 is coming, and probably with a bang. Katy Huberty of Morgan Stanley, after her tour in Asia, recently noted that orders for iPhone 6 are 20% higher than they were for iPhone 5s -- up from the previously estimated 12%.  This, of...

Don't Miss BlackBerry’s Resurgence
George Kesarios, The Motley Fool - Motley Fool - Mon Jul 14, 6:00PM CDT
Is BlackBerry experiencing a sort of resurgence? Looking at the stock's price action over the past several weeks, the answer is probably yes. However, even if BlackBerry is not exactly there, yet, the truth of the matter is that the company has so...

Big iPhone 6 might be delayed
at Investor's Business Daily - Mon Jul 14, 5:49PM CDT
Although 4.7-inch and 5.5-inch Apple (AAPL) iPhone 6 models are expected this year, production issues may cause the larger model to be delayed until next year due to problems with the in-cell touch panel and metal casing, says KGI Securities analyst...

Chrome notebook sales grow
at Investor's Business Daily - Mon Jul 14, 5:49PM CDT
Google's (GOOGL) Chromebooks made up 35% of notebook sales in the U.S. commercial sales channel in the 1st 5 months of '14, according to NPD Group data. Sales reportedly surged 250% from a year ago, while Apple (AAPL) MacBook sales rose 20% and...

Citi's Settlement Paves the Way
Chris Hill, Taylor Muckerman, and Jason Moser, The Motley Fool - Motley Fool - Mon Jul 14, 5:00PM CDT
On Monday's MarketFoolery , host Chris Hill, Motley Fool One analyst Jason Moser, and Stock Advisor Canada analyst Taylor Muckerman, look at big banks and the banking industry. Chris notes that Citigroup   was up today and that its Q2 profits...

Apple's Appeal Strengthens After Samsung's Profit Woes
Christopher De Sousa, The Motley Fool - Motley Fool - Mon Jul 14, 4:00PM CDT
Combined, Apple and Samsung account for more than half of the smartphones shipped globally, and drive most of the industry's profits each quarter. But Samsung has seen profits fritter away for the first half of this year, amid strong...

Look for Shares of Apple to Potentially Pullback after Yesterday's 1.29% Rise
Comtex SmarTrend(R) - Mon Jul 14, 3:38PM CDT
Apple (NASDAQ:AAPL) traded in a range yesterday that spanned from a low of $95.65 to a high of $96.89. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $95.95 on volume of 42.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

SmarTrend Watching for Potential Pullback in Shares of Apple After 1.29% Gain
Comtex SmarTrend(R) - Mon Jul 14, 3:37PM CDT
Apple (NASDAQ:AAPL) traded in a range yesterday that spanned from a low of $95.65 to a high of $96.89. Yesterday, the shares gained 1.3%, which took the trading range above the 3-day high of $95.95 on volume of 42.6 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.

Why Apple and Google Are 2 of the World's Most Respected Companies
Mark Morelli, The Motley Fool - Motley Fool - Mon Jul 14, 3:28PM CDT
A famous actor and former California governor once proclaimed in a movie that he'd be back. A famous tech company could have issued a similar statement last year, too, after it was booted from the top of a list of the world's most respected...

Two Possible Apple, Inc. Product Delays -- Worth Fretting Over?
Daniel Sparks, The Motley Fool - Motley Fool - Mon Jul 14, 3:00PM CDT
A couple of new reports suggest two of Apple 's major upcoming products may be getting delayed. Is this a problem investors should be worried about? Probably not. And judging from Apple's stock that opened in the green this morning, the market...

The Single Best ETF Strategy for Second Half of the Year
at The Street - Mon Jul 14, 2:15PM CDT
It's mid-year: Here's one standout ETF, plus how to evaluate the others you hold (in addition to equities), to help you weather 2014.

Why Microsoft Should Extend Mainstream Support for Windows 7
Joseph Gacinga, The Motley Fool - Motley Fool - Mon Jul 14, 2:00PM CDT
Microsoft is beating the drum in regards to the end of mainstream support of key Windows products such as Windows 7, Windows Server 2003, and Office 2010 Service Pack 1. Mainstream support for Windows 7 is scheduled to come to an end on Jan. 13,...
Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 34

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 39

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 31

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 45

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 41

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading

Top 5 Most Recently Viewed Articles

Celebrating Green Leaders: 2024 IGIHOF Induction Ceremony Details

Updated Category News Views 276

Celebrating the Newest Inductees into the Green Industry The International Green Industry Hall of Fame (IGIHOF) is gearing up for its annual induction ceremony, where it will honor nine remarkable individuals and organizations dedicated to advancing ecological sustainability. This year, the event will take place within the environment of innovative learning at the...

Continue Reading
Governor Advocates for Controlled Substances Decriminalization

Updated Category News Views 48

Governor Advocates for Controlled Substances Decriminalization Puerto Rico’s Governor Pedro Pierluisi Urrutia has made a compelling argument for decriminalizing the consumption of all controlled substances. His stance primarily addresses the pressing fentanyl crisis affecting communities across the island. Governor Pierluisi highlighted, "I have said since the 90s that...

Continue Reading
Odyssey Marine Exploration: Navigating Stock Market Challenges

Updated Category News Views 221

Recent Trends in Odyssey Marine Exploration Stock Odyssey Marine Exploration, Inc. (NASDAQ: OMEX) has seen its stock price fluctuate significantly in recent times. After an arbitration award involving the company and the United Mexican States was announced, the stock experienced a sharp decline, which has sparked concerns about its future path. Decoding the Arbitration...

Continue Reading
Decent Holding Inc. Unveils US$8 Million Offering for Growth

Updated Category News Views 101

Decent Holding Inc. Announced Its New Offering In a significant move within the wastewater treatment sector, Decent Holding Inc. (NASDAQ: DXST) shared exciting news about their latest financing initiative. The company has introduced a registered offering amounting to US$8 million. This offering involves 13,333,333 Class A ordinary shares priced at US$0.60 each, along with...

Continue Reading
Nexxen Strengthens Data Strategies with Eric Solomon's Leadership

Updated Category News Views 208

Nexxen Appoints Eric Solomon to Drive Data Strategy In a significant move for the advertising technology landscape, Nexxen (NASDAQ: NEXN) has welcomed Eric Solomon as its new Senior Vice President for Product – Data. This appointment underscores Nexxen's dedication to a data-driven approach that aims to enhance growth and success for advertisers and media companies...

Continue Reading